Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about US FDA granted Nevro's Senza spinal cord stimulation system
Nevro Corp., a medical device company focused on developing solutions in the neuromodulation spacea, has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system. This is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
- Read more about Neusoft Medical Systems launch NeuViz 128 CT for global markets
Neusoft Medical Systems Co., Ltd. manufactures medical equipment, and provides medical IT solutions and healthcare services, introduced NeuViz 128 CT for the global markets. The products are being exported to South Asia, North Africa and other international markets. It is leading-edge technologies and innovations to create super-fine and low dose images.
- Read more about Stempeutics gets patent in China for Stempeucel
Stempeutics Research, a part of the Manipal Education and Medical Group (MEMG), has received process patent from the State Intellectual Property Office of China (SIPO) for its novel stem-cell based drug Stempeucel for the treatment of Critical Limb Ischemia (CLI), a progressive form of peripheral arterial disease.
- Read more about Ajanta Pharma net surges by 20% in Q4, share at 300% for 2014-15
Ajanta Pharma posted satisfactory financial performance for the fourth quarter ended March 2015 and its standalone net profit increased by 20.3 per cent to Rs. 84.31 crore from Rs. 70.09 crore in the corresponding period of last year. EBIDTA increased by 22 per cent to Rs. 140.72 crore from Rs. 115.36 crore. Its net sales rise up by 19.7 per cent to Rs. 360.36 crore from Rs. 301.14 crore. Export is 67 per cent of the revenue for the quarter. R&D expenditure increased to Rs. 24 crore from Rs. 11 crore in the similar period of last year. The board of directors has approved equity share of 300 per cent for the year 2014-15.
- Read more about GSK net earnings to £8,038 mn in Q1 boosts by other operating income
GlaxoSmithKline (GSK), has posted net profit of £8,038 million during the first quarter ended March 2015 as against £719 million in the corresponding period of last year, mainly due to other operating income of £8,712 million. Its sales remained almost stagnant at £5,622 million as compared to £5,613 million. Its R&D expenditure increased to £867 million from £859 million.

[adsense:336x280:8701650588]
- Read more about Mylan launch generic Seasonale tablets in US market
Mylan NV, a global pharmaceutical company, launched levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, generic version of Teva's Seasonale tablets, in the US.
- Read more about Torrent Pharma gain entire stake in Zyg Pharma
Torrent Pharmaceuticals earn 100 percent equity stake in Zyg Pharma Pvt Ltd, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions, for undisclosed price.
- Read more about Taiwan’s Apex Medical Corporation forays into Indian market
Apex Medical Corporation has made its debut into Indian market with the launch of its three main product verticals - respiratory, support surface and autoclaves primarily as their core offering in India.
- Read more about QB1 System for quadriceps muscle atrophy treatment introduced by CyMedica
CyMedica Orthopedics, Inc., has commercially launched the CyMedica QB1 System for the treatment of quadriceps muscle atrophy. The CyMedica QB1 System has introduced at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine (AANA) annual meeting in Los Angeles recently.
- Read more about Biocon's net profit pushes by Exceptional items over 78% in Q4
Biocon, a leading innovation-led bio-pharmaceutical company, has announced satisfactory financial performance during the fourth quarter ended March 2014. Its consolidated net profit, after exceptional income of Rs. 105 crore on account of sale of Syngene shares, increased by 78.2 per cent to Rs. 201.54 crore from Rs. 113.08 crore in the corresponding period of last year. Operating profit jumped 4.7 percent year-on-year to Rs 202 crore for the quarter ended March 2015 from Rs 193 crore in the same quarter last year.Profit before tax and exceptional income also improved by only 4 per cent to Rs. 143.54 crore from Rs. 138.06 crore. EPS moved up to Rs. 10.08 from Rs. 5.76 crore. Its consolidated net sales increased by 14.9 per cent to Rs. 830.38 crore during the fourth quarter from Rs. 722.59 crore in the same period of last year. Its pharma sales increased by 10.8 per cent to Rs. 594.91 crore from Rs. 536.77 crore and that of contract research & manufacturing services improved by 27.7 per cent to Rs. 248.92 crore from Rs. 194.90 crore.